BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18518765)

  • 1. Future directions in the management of epithelial ovarian cancer.
    Blagden S; Gabra H
    Future Oncol; 2008 Jun; 4(3):403-11. PubMed ID: 18518765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and treatment of recurrent epithelial ovarian carcinoma].
    Wu XF; Chen HZ; Han DF
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):664-6. PubMed ID: 14728851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pay more attention to the surveillance and deal with the recurrence in ovarian cancer].
    Shen K
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):657-8. PubMed ID: 14989220
    [No Abstract]   [Full Text] [Related]  

  • 4. How to follow-up patients with epithelial ovarian cancer.
    Miller RE; Rustin GJ
    Curr Opin Oncol; 2010 Sep; 22(5):498-502. PubMed ID: 20498597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
    Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
    Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
    Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
    Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of risk factors for epithelial ovarian cancer recurrence].
    Liu S; Liu JH; Huang H; Peng XP; Wang YM
    Ai Zheng; 2003 Nov; 22(11):1197-200. PubMed ID: 14613652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
    Agarwal R; Kaye SB
    Nat Rev Cancer; 2003 Jul; 3(7):502-16. PubMed ID: 12835670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
    Baumann KH; Wagner U; du Bois A
    Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced ovarian cancer: current research and perspectives.
    Marchetti C; Pisano C; Facchini G; Bruni GS; Magazzino FP; Losito S; Pignata S
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):47-60. PubMed ID: 20014885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer.
    Hennessy BT; Coleman RL; Markman M
    Lancet; 2009 Oct; 374(9698):1371-82. PubMed ID: 19793610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer - diagnosis and management.
    Davy M
    Aust Fam Physician; 2007 Mar; 36(3):130-3. PubMed ID: 17339974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ledermann JA; Raja FA; Fotopoulou C; Gonzalez-Martin A; Colombo N; Sessa C;
    Ann Oncol; 2013 Oct; 24 Suppl 6():vi24-32. PubMed ID: 24078660
    [No Abstract]   [Full Text] [Related]  

  • 15. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials.
    Korkmaz T; Seber S; Basaran G
    Crit Rev Oncol Hematol; 2016 Feb; 98():180-8. PubMed ID: 26603345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
    Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M;
    Eur J Cancer; 2017 Jun; 78():133-138. PubMed ID: 28448857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of epithelial ovarian cancer: overdue for a major rethink.
    Hoskins P
    Curr Oncol Rep; 2013 Jun; 15(3):204-6. PubMed ID: 23483376
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials referral resource. Current clinical trials in epithelial ovarian cancer.
    Trimble E; Valmonte CM; Cheson BD
    Oncology (Williston Park); 2000 May; 14(5):678, 683-4, 687-8 passim. PubMed ID: 10853460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.